[New therapeutic approaches to age dependent macular degeneration].
Holz
F G
FG
D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D020256:Choroidal Neovascularization / Q000209:etiology / Q000628:therapy; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000502:physiology; D005544:Forecasting; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D008062:Lipofuscin / Q000378:metabolism; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000502:physiology; D008268:Macular Degeneration / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D018345:Mice, Knockout; D010641:Phenotype; D010857:Pigment Epithelium of Eye / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D012106:Research; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D044465:White People
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008062:Lipofuscin; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors